Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Other Non-Current Liabilities (2016 - 2022)

Historic Other Non-Current Liabilities for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Q3 2022 value amounting to $5.7 million.

  • Avadel Pharmaceuticals' Other Non-Current Liabilities rose 4321.08% to $5.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.7 million, marking a year-over-year increase of 4321.08%. This contributed to the annual value of $3.9 million for FY2021, which is 700.38% down from last year.
  • Latest data reveals that Avadel Pharmaceuticals reported Other Non-Current Liabilities of $5.7 million as of Q3 2022, which was up 4321.08% from $5.7 million recorded in Q2 2022.
  • In the past 5 years, Avadel Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $14.3 million in Q1 2018 and a low of $3.8 million during Q1 2022
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $5.7 million (2022), whereas its average is $8.2 million.
  • In the last 5 years, Avadel Pharmaceuticals' Other Non-Current Liabilities soared by 15969.39% in 2018 and then tumbled by 6465.79% in 2020.
  • Over the past 5 years, Avadel Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $14.0 million in 2018, then plummeted by 36.63% to $8.9 million in 2019, then crashed by 52.53% to $4.2 million in 2020, then dropped by 7.0% to $3.9 million in 2021, then soared by 46.21% to $5.7 million in 2022.
  • Its Other Non-Current Liabilities was $5.7 million in Q3 2022, compared to $5.7 million in Q2 2022 and $3.8 million in Q1 2022.